AR063258A1 - Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos. - Google Patents
Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.Info
- Publication number
- AR063258A1 AR063258A1 ARP070104514A ARP070104514A AR063258A1 AR 063258 A1 AR063258 A1 AR 063258A1 AR P070104514 A ARP070104514 A AR P070104514A AR P070104514 A ARP070104514 A AR P070104514A AR 063258 A1 AR063258 A1 AR 063258A1
- Authority
- AR
- Argentina
- Prior art keywords
- halogen
- alkyl
- ring
- hydrogen
- triazolyl
- Prior art date
Links
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- 208000019553 vascular disease Diseases 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical group 0.000 abstract 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 3
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 abstract 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 125000002883 imidazolyl group Chemical group 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 125000004849 alkoxymethyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- -1 cyano, tetrazolyl Chemical group 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229910052701 rubidium Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 208000037911 visceral disease Diseases 0.000 abstract 1
- 230000009278 visceral effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/803—Processes of preparation
- C07D213/807—Processes of preparation by oxidation of pyridines or condensed pyridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Derivados de 2-aminocarbonil-piridina y su uso como antagonistas del receptor P2Y12 en el tratamiento y/o la prevencion de enfermedades vasculares periféricas, viscerales, hepáticas y renales, de enfermedades cardiovasculares y cerebrovasculares o estados asociados con la agregacion de plaquetas, incluyendo trombosis en humanos y en otros animales. Reivindicacion 1: Un compuesto de formula 1 en donde R1 representa un halogeno o un anillo imidazolilo, pirazolilo, 1,2,3-triazolilo o 1,2,4- triazolilo, anillo que puede estar sustituido con un grupo metilo, o también R1 representa fenilo opcionalmente sustituido 1 a 3 mediante substituyentes cada uno seleccionado independientemente desde el grupo que consiste en halogeno, metilo, metoxilo, trifluorometilo y trifluorometoxilo; W representa un enlace y R2 representa H, halogeno, alquilo, hidroxialquilo, alcoxialquilo, cicloalquilo, arilo o heteroarilo; o W representa -O- o -S- y R2 representa alquilo, cicloalquilo, arilo o heterociclilo; o W representa -NR3-, R2 representa alquilo, hidroxialquilo, o alcoxialquilo y R3 representa hidrogeno o alquilo; o W representa -C:::C- y R2 representa hidroxialquilo o alcoxialquilo; o W representa -NR3- y R2 y R3 forman, en conjunto con el nitrogeno que los porta, un anillo heterocíclico de 4 a 7 miembros en donde los miembros necesarios para completar dicho anillo heterocíclico son cada uno seleccionado de manera independiente desde -CH2- y -CHRx-, sin embargo se entiende que dicho anillo heterocíclico no contiene más que un miembro -CHRx-, Rx representando hidroxilo, hidroximetilo, alcoximetilo o alcoxilo; o también W representa -NR3- y R2 y R3 forman, en conjunto con el nitrogeno que los porta, un anillo imidazolilo, pirazolilo, 1,2,3-triazolilo o 1,2,4-triazolilo, anillo que opcionalmente puede estar sustituido con un grupo metilo; Ra representa hidrogeno o F y Rb representa H, o Ra representa hidrogeno y Rb representa alcoxilo; cada uno de R4 y R5 representa de manera independiente hidrogeno o metilo; R6 representa alcoxilo; e Y representa alquileno o fenilalquileno, y Z representa -OH, -COOH , ciano, tetrazolilo o -COOR7; R7 representando alquilo; se entiende que: cuando R1 representa un halogeno entonces W y R2 no son tales que W representa un enlace y R2 representa hidrogeno o halogeno, y cuando Ra representa fluor entonces: i) R1 representa fenilo opcionalmente substituido una vez con F, metilo, metoxilo, trifluorometilo o trifluorometoxilo, ii) W no representa -O- o -S-, y iii) si W es un enlace, entonces R2 no representa hidrogeno; o una sal de un tal compuesto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2006053773 | 2006-10-13 | ||
| IB2006053817 | 2006-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063258A1 true AR063258A1 (es) | 2009-01-14 |
Family
ID=39167796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104514A AR063258A1 (es) | 2006-10-13 | 2007-10-11 | Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8093250B2 (es) |
| EP (1) | EP2081903B1 (es) |
| JP (1) | JP5341763B2 (es) |
| KR (1) | KR101525260B1 (es) |
| AR (1) | AR063258A1 (es) |
| AU (1) | AU2007305925A1 (es) |
| BR (1) | BRPI0720193A2 (es) |
| CA (1) | CA2664579C (es) |
| CL (1) | CL2007002920A1 (es) |
| ES (1) | ES2473609T3 (es) |
| IL (1) | IL198059A0 (es) |
| MA (1) | MA30868B1 (es) |
| MX (1) | MX2009003724A (es) |
| NO (1) | NO20091838L (es) |
| RU (1) | RU2009117705A (es) |
| TW (1) | TW200823190A (es) |
| WO (1) | WO2008044217A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
| AR063518A1 (es) | 2006-10-25 | 2009-01-28 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis |
| NZ586445A (en) | 2007-11-29 | 2012-06-29 | Actelion Pharmaceuticals Ltd | Phosphonic acid derivates and their use as p2y12 receptor antagonists |
| CN104058999A (zh) | 2008-02-29 | 2014-09-24 | 伊沃泰克股份公司 | 酰胺化合物、组合物及其应用 |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| EP2346825A2 (en) * | 2008-09-18 | 2011-07-27 | Evotec AG | Modulators of p2x3 receptor activity |
| US8288385B2 (en) | 2009-04-08 | 2012-10-16 | Actelion Pharmaceuticals Ltd. | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines |
| SG175297A1 (en) | 2009-04-22 | 2011-12-29 | Actelion Pharmaceuticals Ltd | Thiazole derivatives and their use as p2y12 receptor antagonists |
| US9120752B2 (en) | 2010-07-16 | 2015-09-01 | Purdue Pharma, L.P. | Pyridine compounds as sodium channel blockers |
| EP2750676B1 (en) | 2011-08-30 | 2018-01-10 | University of Utah Research Foundation | Methods and compositions for treating nephrogenic diabetes insipidus |
| WO2013136170A1 (en) | 2012-03-16 | 2013-09-19 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
| WO2014096941A1 (en) | 2012-12-20 | 2014-06-26 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
| US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
| SI3515924T1 (sl) | 2016-09-22 | 2022-04-29 | Idorsia Pharmaceuticals Ltd. | Kristalinične oblike |
| TWI765002B (zh) | 2017-03-15 | 2022-05-21 | 瑞士商愛杜西亞製藥有限公司 | 受體拮抗劑之皮下投藥 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5373586A (en) | 1976-12-09 | 1978-06-30 | Mitsubishi Chem Ind Ltd | New penicillin derivatives |
| CA2020437A1 (en) | 1989-07-05 | 1991-01-06 | Yoshihide Fuse | Cinnamamide derivative |
| IL123986A (en) * | 1997-04-24 | 2011-10-31 | Organon Nv | Medicinal compounds |
| AU742853B2 (en) * | 1997-07-31 | 2002-01-17 | Ube Industries, Ltd. | N-acylamino acid amide compounds and intermediates for preparation thereof |
| ES2248084T3 (es) * | 1999-06-14 | 2006-03-16 | Eli Lilly And Company | Inhibidores de serinproteasa. |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| UA83648C2 (ru) * | 2002-12-11 | 2008-08-11 | Шеринг Акциенгезельшафт | Антагонисты аденозиндифосфатного рецептора тромбоцитов |
| TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| EP1940814B1 (en) | 2005-10-21 | 2013-05-22 | Actelion Pharmaceuticals Ltd. | Piperazine derivatives as antimalarial agents |
| CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
| AR063518A1 (es) | 2006-10-25 | 2009-01-28 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis |
| NZ586445A (en) | 2007-11-29 | 2012-06-29 | Actelion Pharmaceuticals Ltd | Phosphonic acid derivates and their use as p2y12 receptor antagonists |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| US8288385B2 (en) | 2009-04-08 | 2012-10-16 | Actelion Pharmaceuticals Ltd. | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines |
| SG175297A1 (en) | 2009-04-22 | 2011-12-29 | Actelion Pharmaceuticals Ltd | Thiazole derivatives and their use as p2y12 receptor antagonists |
-
2007
- 2007-10-11 CL CL200702920A patent/CL2007002920A1/es unknown
- 2007-10-11 AR ARP070104514A patent/AR063258A1/es unknown
- 2007-10-12 CA CA2664579A patent/CA2664579C/en active Active
- 2007-10-12 AU AU2007305925A patent/AU2007305925A1/en not_active Withdrawn
- 2007-10-12 RU RU2009117705/04A patent/RU2009117705A/ru unknown
- 2007-10-12 MX MX2009003724A patent/MX2009003724A/es unknown
- 2007-10-12 TW TW096138326A patent/TW200823190A/zh unknown
- 2007-10-12 US US12/445,352 patent/US8093250B2/en active Active
- 2007-10-12 EP EP07826720.0A patent/EP2081903B1/en active Active
- 2007-10-12 WO PCT/IB2007/054155 patent/WO2008044217A2/en active Application Filing
- 2007-10-12 JP JP2009531969A patent/JP5341763B2/ja active Active
- 2007-10-12 BR BRPI0720193-1A patent/BRPI0720193A2/pt not_active IP Right Cessation
- 2007-10-12 KR KR1020097009599A patent/KR101525260B1/ko active IP Right Grant
- 2007-10-12 ES ES07826720.0T patent/ES2473609T3/es active Active
-
2009
- 2009-04-07 IL IL198059A patent/IL198059A0/en unknown
- 2009-05-06 MA MA31845A patent/MA30868B1/fr unknown
- 2009-05-12 NO NO20091838A patent/NO20091838L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MA30868B1 (fr) | 2009-11-02 |
| NO20091838L (no) | 2009-05-12 |
| US8093250B2 (en) | 2012-01-10 |
| KR20090086075A (ko) | 2009-08-10 |
| JP5341763B2 (ja) | 2013-11-13 |
| CL2007002920A1 (es) | 2008-06-06 |
| JP2010505940A (ja) | 2010-02-25 |
| CA2664579C (en) | 2014-09-30 |
| RU2009117705A (ru) | 2010-11-20 |
| WO2008044217A3 (en) | 2008-06-19 |
| BRPI0720193A2 (pt) | 2013-12-31 |
| EP2081903A2 (en) | 2009-07-29 |
| WO2008044217A2 (en) | 2008-04-17 |
| TW200823190A (en) | 2008-06-01 |
| MX2009003724A (es) | 2009-04-22 |
| KR101525260B1 (ko) | 2015-06-02 |
| CA2664579A1 (en) | 2008-04-17 |
| AU2007305925A1 (en) | 2008-04-17 |
| ES2473609T3 (es) | 2014-07-07 |
| EP2081903B1 (en) | 2014-05-07 |
| US20100035895A1 (en) | 2010-02-11 |
| IL198059A0 (en) | 2009-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063258A1 (es) | Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos. | |
| AR071652A1 (es) | Derivados 2- fenil-piridina substituidos | |
| AR069494A1 (es) | Derivados de acidos fosfonicos | |
| AR056992A1 (es) | Derivados de pirimidina | |
| HRP20180483T1 (hr) | Spoj kinolona | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR074426A1 (es) | Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende | |
| RS54518B1 (en) | Bicyclic Heterocyclic Compounds as Protein Tyrosine Kinase Inhibitors | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR057770A1 (es) | Inhibidores de la p38-map-quinasa y composicion farmaceutica | |
| AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
| AR112264A1 (es) | Derivados de oxoftalazina y oxocinolina como antagonistas de los receptores s1p, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades fibróticas, autoinmunes y proliferativas | |
| AR080865A1 (es) | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. | |
| AR055431A1 (es) | Derivados del acido 4-amino-tieno[3,2-c]piridina-7-carboxilico | |
| PE20161315A1 (es) | Compuestos de pirazolona y usos de los mismos | |
| EA201190142A1 (ru) | Производные пиразола, используемые в качестве антагонистов рецептора ccr4 | |
| MY193597A (en) | Novel pyrrolidine compound and application as melanocortin receptor agonist | |
| AR071653A1 (es) | Derivados 2-fenil-4-ciclopropil-pirimidina | |
| EA201600435A1 (ru) | Кристаллическая форма (s)-(2-(6-хлор-7-метил-1н-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора | |
| AR054508A1 (es) | Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
| AR085750A1 (es) | Derivados de pirazolo-pirimidina | |
| EA201600436A1 (ru) | Кристаллическая солевая форма (s)-(2-(6-хлор-7-метил-1h-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора | |
| AR062013A1 (es) | Derivados cromenos o tiocromenos carboxamidas, su procedimiento de preparacion y sus aplicaciones en terapeutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |